Aclaris Therapeutics, Inc. (NASDAQ:ACRS)‘s stock had its “buy” rating reiterated by Cantor Fitzgerald in a report issued on Tuesday.

The analysts wrote, “We hosted our annual Cantor Fitzgerald Healthcare Conference in New York today, with ACRS in attendance.””

Several other analysts also recently weighed in on ACRS. BidaskClub downgraded Aclaris Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. ValuEngine downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, September 12th. JMP Securities reiterated an “outperform” rating and set a $39.00 price target on shares of Aclaris Therapeutics in a research note on Friday, September 8th. Jefferies Group LLC reiterated a “buy” rating and set a $36.00 price target on shares of Aclaris Therapeutics in a research note on Monday, July 31st. Finally, Guggenheim reiterated a “buy” rating and set a $40.00 price target on shares of Aclaris Therapeutics in a research note on Tuesday, July 4th. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. Aclaris Therapeutics has a consensus rating of “Hold” and an average price target of $40.00.

Aclaris Therapeutics (NASDAQ ACRS) traded down 0.27% on Tuesday, reaching $25.93. The company’s stock had a trading volume of 202,932 shares. The firm’s 50 day moving average price is $25.99 and its 200-day moving average price is $27.57. The company’s market capitalization is $693.26 million. Aclaris Therapeutics has a 1-year low of $20.15 and a 1-year high of $33.25.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.12. Equities analysts forecast that Aclaris Therapeutics will post ($3.10) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Cantor Fitzgerald Reaffirms Buy Rating for Aclaris Therapeutics, Inc. (ACRS)” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/26/cantor-fitzgerald-reaffirms-buy-rating-for-aclaris-therapeutics-inc-acrs.html.

In related news, Director Andrew N. Schiff bought 108,601 shares of the stock in a transaction dated Wednesday, August 16th. The shares were purchased at an average price of $23.02 per share, for a total transaction of $2,499,995.02. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 16.30% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. Rosenblum Silverman Sutton S F Inc. CA boosted its stake in shares of Aclaris Therapeutics by 17.3% in the second quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 38,400 shares of the biotechnology company’s stock worth $1,041,000 after buying an additional 5,650 shares during the last quarter. Franklin Resources Inc. boosted its stake in shares of Aclaris Therapeutics by 55.4% in the second quarter. Franklin Resources Inc. now owns 1,955,381 shares of the biotechnology company’s stock worth $53,030,000 after buying an additional 697,104 shares during the last quarter. American International Group Inc. boosted its stake in shares of Aclaris Therapeutics by 31.3% in the first quarter. American International Group Inc. now owns 6,804 shares of the biotechnology company’s stock worth $203,000 after buying an additional 1,623 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in shares of Aclaris Therapeutics by 6.6% in the first quarter. Schwab Charles Investment Management Inc. now owns 43,961 shares of the biotechnology company’s stock worth $1,311,000 after buying an additional 2,736 shares during the last quarter. Finally, EcoR1 Capital LLC boosted its stake in shares of Aclaris Therapeutics by 62.6% in the first quarter. EcoR1 Capital LLC now owns 673,100 shares of the biotechnology company’s stock worth $20,072,000 after buying an additional 259,100 shares during the last quarter. Hedge funds and other institutional investors own 95.79% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.